.jpg "Blueprint Medicines (NASDAQ: BPMC)")
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Blueprint Medicines (BPMC) today. The company’s shares opened today at $96.99, close to its 52-week high of $100.76.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 3.3% and a 54.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Applied Therapeutics Inc.
Currently, the analyst consensus on Blueprint Medicines is a Strong Buy with an average price target of $113.67, which is a 17.2% upside from current levels. In a report issued on June 3, Wedbush also reiterated a Buy rating on the stock with a $104 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $100.76 and a one-year low of $44.58. Currently, Blueprint Medicines has an average volume of 515.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.
